Pfizer Faces Patent Infringement Lawsuit from Enanta Pharmaceuticals Over COVID-19 Drug Paxlovid

Pfizer is facing a new legal challenge over its COVID-19 antiviral drug, Paxlovid. Enanta Pharmaceuticals has filed a lawsuit against Pfizer, alleging patent infringement related to the billion-dollar medication. This marks another instance in which Pfizer’s intellectual property surrounding Paxlovid has come under scrutiny.

The pharmaceutical company responded to the lawsuit by expressing confidence in its ownership of the drug’s intellectual property. Paxlovid, which has played a significant role in treating COVID-19 patients globally, remains one of Pfizer’s key products. The legal dispute adds to ongoing challenges for the company as it navigates questions about patents and proprietary rights tied to its high-profile treatment.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

Date: August 20, 2025

Author

Mark Chiang